Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24299734 | 0.87 | KMT2A (0.38) | KMT2AMDM2TLR2BMP1MDM4 | |
| SCHEMBL29929002 | 0.84 | MDM2 (0.32) | KMT2AMDM2TLR2BMP1MDM4 | |
| SCHEMBL20233444 | 0.83 | GAA (0.34) | KMT2A | |
| SCHEMBL25631518 | 0.82 | KMT2A (0.45) | KMT2AMDM2TLR2MDM4TP53 | |
| SCHEMBL24115355 | 0.79 | TLR2 (0.41) | KMT2AMDM2TLR2BMP1MDM4 | |
| SCHEMBL14765350 | 0.79 | KMT2A (0.46) | KMT2ATLR2CASP3 | |
| SCHEMBL31469016 | 0.79 | KMT2A (0.46) | KMT2ATLR2CASP3 | |
| SCHEMBL4919160 | 0.78 | GAA (0.36) | KMT2A | |
| SCHEMBL889833 | 0.78 | KMT2A (0.46) | KMT2AMDM2TLR2BMP1MDM4 | |
| SCHEMBL3423921 | 0.78 | KMT2A (0.46) | KMT2AMDM2TLR2BMP1MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4720298-A1 | TREATMENT OF FGG RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4687920-A2 | TREATMENT OF FGG RELATED HEARING DISORDERS | EMPIRICO INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250368990-A1 | TREATMENT OF MS4A4E RELATED DISEASES AND DISORDERS | EMPIRICO INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250361399-A1 | FLUORESCENT DYES WITH LARGE STOKES SHIFT | ROCHE MOLECULAR SYSTEMS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4643948-A2 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250333732-A1 | TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS | EMPIRICO INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4638749-A2 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4634391-A2 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250313841-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. | 2025-10-09 | — | — | US | disclosed |
| WO-2022266132-A1 | TREATMENT OF PLIN1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266037-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266045-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022261005-A1 | TREATMENT OF ANGPTL4 RELATED DISEASES | EMPIRICO INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220340907-A1 | OLIGONUCLEOTIDES FOR TREATMENT OF ANGIOPOIETIN LIKE 4 (ANGPTL4) RELATED DISEASES | EMPIRICO INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4072562-A1 | OLIGONUCLEOTIDES FOR TREATMENT OF ANGIOPOIETIN LIKE 4 (ANGPTL4) RELATED DISEASES | EMPIRICO INC. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11464865-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2022-10-11 | — | — | US | disclosed |
| US-11377658-B2 | Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseases | EMPIRICO INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3985116-A1 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | City of Hope (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3980451-A1 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | Yeda Research and Development Co. Ltd (IL) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464865-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | STAT3, STAT1, STAT4 | KMT2A 1728/4885MDM2 3336/4885TLR2 970/4885 |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | STAT3, NSUN2, STAT1 | KMT2A 761/4885MDM2 2808/4885TLR2 835/4885 |
| US-20250368990-A1 | TREATMENT OF MS4A4E RELATED DISEASES AND DISORDERS | SNRPE, DCLRE1B, MRPS34 | KMT2A 768/4885MDM2 3903/4885TLR2 4870/4885 |
| US-20250313841-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | MST1, MSTN, MST1R | KMT2A 3230/4885MDM2 1456/4885TLR2 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.